human papillomavirus quadrivalent vaccine + rLP2086

This is a **combination vaccine**, pairing the human papillomavirus quadrivalent vaccine with **rLP2086** (bivalent recombinant lipoprotein 2086), also known as Trumenba. - The human papillomavirus quadrivalent vaccine is designed to protect against infection by four HPV types (typically HPV 6, 11, 16, and 18), preventing diseases including cervical cancer and genital warts. - **rLP2086** (Trumenba) is a bivalent, recombinant **vaccine** targeting Neisseria meningitidis serogroup B, containing two recombinant lipidated factor H binding protein antigens (fHBP subfamily A05 and B01). These proteins induce the production of bactericidal antibodies that protect against meningococcal group B infections. - rLP2086's mechanism works by targeting factor H binding protein on the bacterial surface, eliciting broadly protective immune responses in adolescents and young adults[1][3][4].

Brand names

Trumenba

Other names

meningococcal group B vaccine [bivalent recombinant lipoprotein rLP2086]bivalent rLP2086